Bone stroma-derived cells change coregulators recruitment to androgen receptor and decrease cell proliferation in androgen-sensitive and castration-resistant prostate cancer cells

被引:5
|
作者
Villagran, Marcelo A. [1 ]
Gutierrez-Castro, Francisco A. [1 ]
Pantoja, Diego F. [1 ]
Alarcon, Jose C. [1 ]
Farina, Macarena A. [1 ]
Amigo, Romina F. [1 ]
Munoz-Godoy, Natalia A. [1 ]
Pinilla, Mabel G. [2 ]
Pena, Eduardo A. [3 ]
Gonzalez-Chavarria, Ivan [3 ]
Toledo, Jorge R. [3 ]
Rivas, Coralia I. [3 ]
Vera, Juan C. [3 ]
McNerney, Eileen M. [1 ]
Onate, Sergio A. [1 ,2 ,4 ]
机构
[1] Univ Concepcion, Mol Endocrinol & Oncol Lab, Concepcion, Chile
[2] Univ Concepcion, Dept Med Specialties, Sch Med, Concepcion, Chile
[3] Univ Concepcion, Dept Physiopathol, Sch Biol Sci, Concepcion, Chile
[4] SUNY Buffalo, Dept Urol, Buffalo, NY 14260 USA
关键词
Androgens; Transcription; Bone stroma; Prostate cancer; GROWTH;
D O I
10.1016/j.bbrc.2015.10.009
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Prostate cancer (Cap) bone metastasis is an early event that remains inactive until later-stage progression. Reduced levels of circulating androgens, due to andropause or androgen deprivation therapies, alter androgen receptor (AR) coactivator expression. Coactivators shift the balance towards enhanced AR-mediated gene transcription that promotes progression to androgen-resistance. Disruptions in coregulators may represent a molecular switch that reactivates latent bone metastasis. Changes in AR-mediated transcription in androgen-sensitive LNCaP and androgen-resistant C4-2 cells were analyzed for AR coregulator recruitment in co-culture with Saos-2 and THP-1. The Saos-2 cell line derived from human osteosarcoma and THP-1 cell line representing human monocytes were used to display osteoblast and osteoclast activity. Increased AR activity in androgen-resistant C4-2 was due to increased AR expression and SRC1/TIF2 recruitment and decreased SMRT/NCoR expression. AR activity in both cell types was decreased over 90% when co-cultured with Saos-2 or THP-1 due to dissociation of AR from the SRC1/TIF2 and SMRT/NCoR coregulators complex, in a ligand-dependent and cell-type specific manner. In the absence of androgens, Saos-2 decreased while THP-1 increased proliferation of LNCaP cells. In contrast, both Saos-2 and THP-1 decreased proliferation of C4-2 in absence and presence of androgens. Global changes in gene expression from both CaP cell lines identified potential cell cycle and androgen regulated genes as mechanisms for changes in cell proliferation and AR-mediated transactivation in the context of bone marrow stroma cells. (C) 2015 Elsevier Inc. All rights reserved.
引用
收藏
页码:1039 / 1045
页数:7
相关论文
共 50 条
  • [41] Annexin-A7 protects normal prostate cells and induces distinct patterns of RB-associated cytotoxicity in androgen-sensitive and -resistant prostate cancer cells
    Torosyan, Yelizaveta
    Simakova, Olga
    Naga, Shanmugam
    Mezhevaya, Katerina
    Leighton, Ximena
    Diaz, Juan
    Huang, Wei
    Pollard, Harvey
    Srivastava, Meera
    INTERNATIONAL JOURNAL OF CANCER, 2009, 125 (11) : 2528 - 2539
  • [42] Down-Regulation of the Androgen Receptor by G-Quadruplex Ligands Sensitizes Castration-Resistant Prostate Cancer Cells to Enzalutamide
    Tassinari, Martina
    Cimino-Reale, Graziella
    Nadai, Matteo
    Doria, Filippo
    Butovskaya, Elena
    Recagni, Marta
    Freccero, Mauro
    Zaffaroni, Nadia
    Richter, Sara N.
    Folini, Marco
    JOURNAL OF MEDICINAL CHEMISTRY, 2018, 61 (19) : 8625 - 8638
  • [43] High expression of TROP2 characterizes different cell subpopulations in androgen-sensitive and androgen-independent prostate cancer cells
    Xie, Jinhan
    Molck, Christina
    Paquet-Fifield, Sophie
    Butler, Lisa
    Bioresource, Australian Prostate Cancer
    Sloan, Erica
    Ventura, Sabatino
    Hollande, Frederic
    ONCOTARGET, 2016, 7 (28) : 44492 - 44504
  • [44] Androgen receptor: what we know and what we expect in castration-resistant prostate cancer
    Zhonglin Cai
    Weijie Chen
    Jianzhong Zhang
    Hongjun Li
    International Urology and Nephrology, 2018, 50 : 1753 - 1764
  • [45] BAY 1024767 blocks androgen receptor mutants found in castration-resistant prostate cancer patients
    Sugawara, Tatsuo
    Lejeune, Pascale
    Koehr, Silke
    Neuhaus, Roland
    Faus, Hortensia
    Gelato, Kathy A.
    Busemann, Matthias
    Cleve, Arwed
    Luecking, Ulrich
    von Nussbaum, Franz
    Brands, Michael
    Mumberg, Dominik
    Jung, Klaus
    Stephan, Carsten
    Haendler, Bernard
    ONCOTARGET, 2016, 7 (05) : 6015 - 6028
  • [46] Androgen receptor: what we know and what we expect in castration-resistant prostate cancer
    Cai, Zhonglin
    Chen, Weijie
    Zhang, Jianzhong
    Li, Hongjun
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2018, 50 (10) : 1753 - 1764
  • [47] Androgen receptor antagonist Treatment of metastatic castration-resistant prostate cancer Treatment of metastatic breast cancer
    Culig, Zoran
    DRUGS OF THE FUTURE, 2023, 48 (01) : 15 - 21
  • [48] 20-HETE/GPR75 pairing modulates the expression and transcriptional activity of the androgen receptor in androgen-sensitive prostate cancer cells
    Cardenas, Sofia
    Colombero, Cecilia
    Cruz, Mariana
    Mormandi, Eduardo
    Adebesin, Adeniyi Michael
    Falck, John R.
    Nowicki, Susana
    MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2023, 559
  • [49] Distinct and specific roles of AKT1 and AKT2 in androgen-sensitive and androgen-independent prostate cancer cells
    Cariaga-Martinez, Ariel E.
    Lopez-Ruiz, Pilar
    Paz Nombela-Blanco, M.
    Motino, Omar
    Gonzalez-Corpas, Ana
    Rodriguez-Ubreva, Javier
    Lobo, Maria V. T.
    Alicia Cortes, M.
    Colas, Begona
    CELLULAR SIGNALLING, 2013, 25 (07) : 1586 - 1597
  • [50] 20-HETE/GPR75 pairing modulates the expression and transcriptional activity of the androgen receptor in androgen-sensitive prostate cancer cells
    Cardenas, Sofia
    Colombero, Cecilia
    Cruz, Mariana
    Mormandi, Eduardo
    Adebesin, Adeniyi Michael
    Falck, John R.
    Nowicki, Susana
    MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2023, 559